Diabetes*
Adult onset of type 2 diabetes accounts for 90 to 95% of all diagnosed cases of diabetes and over 65 million adults in the U.S are at risk.1 As many as 90% of them may not know it.
Those with pre-diabetes are likely to develop Type 2 Diabetes within 10 years unless they take steps to prevent or delay.
Complications of diabetes include heart disease and stroke, blindness, kidney disease, and impaired circulation and nervous system damage that may lead to impaired sensation or amputation of the lower extremities.
Risk factors include:
- Physical inactivity
- Family member with diabetes
- Having or being treated for high blood pressure
- History of cardiovascular disease
- Being severely obese or overweight
A simple blood test, ordered by your physician, may help to assess your risk of developing type 2 diabetes.
Studies show that by increasing physical activity and losing 5 to 7% of your total body weight, you can reduce your diabetes risk by 58% in people under 60 and by just over 70% in people older than 60.
* The LP-IR score is performed in LipoScience's CLIA certified laboratory.
1. Centers for Disease Control and Prevention. Nat’l Diabetes Fact Sheet. 2007. Atlanta, GA: U.S. Department of Health and Human Services, CDC, 2008.
The Pathway to Diabetes*
Development of type 2 diabetes happens over an extended period of time. The disease is known for being symptomless until elevated or even slightly elevated glucose levels are detected during routine physicals.
The bad news is that rising glucose levels are a late symptom in the process. Well before insulin levels begin to rise, the body’s cells become increasingly resistant to the action of its own insulin. The pancreas responds by working to increase insulin production possibly leading to permanent pancreatic failure.
The good news is that there is an earlier indicator of developing insulin resistance, lipoprotein abnormalities. Well before elevations in glucose or insulin levels are identified, changes in lipoprotein metabolism have been occurring.
These changes can be measured by a simple blood test, Lipoprotein Particle Concentration and Size analysis by NMR. Results of this test can help your clinician to detect these lipoprotein changes while there is still time to intervene in the pathway.
Your clinician will recommend basic lifestyle changes that may prevent or delay the onset of type 2 diabetes.
Act early to help prevent disease. Ask your clinician to order the LipoScience LP-IR score* for you.
* The LP-IR score is performed in LipoScience's CLIA certified laboratory.
Diabetes* and Cardiovascular Disease
The Link Between Type 2 Diabetes and Cardiovascular Disease – Cardiometabolic Risk
Cardiometabolic Risk (CMR) combines traditional risk factors for cardiovascular disease (CVD) such as age, sex, smoking, high blood pressure, and decreased HDL cholesterol with history of diabetes with the additional risks of abdominal obesity, physical inactivity and related features of the metabolic syndrome. Together, this cluster of risk factors called CMR, increases a patient’s risk of developing cardiovascular disease (CVD) and type 2 diabetes (T2DM). In order for your clinician to properly evaluate and manage your CVD risk, these factors should be taken into account.
- increased age (men over 35 years, women over 45 years)
- elevated blood pressure (> 130 / > 85 mmHg or on antihypertensive medication)
- abdominal obesity (waist circumference in men > 40 inches and women > 35 inches)
- elevated triglycerides (> 150 mg/dL)
- low high density lipoprotein cholesterol (HDL-C) ( men < 40 mg/dL, women < 50 mg/dL)
- elevated fasting blood glucose(> 110 mg/dL)
- increasing insulin resistance (IR) 1
* The LP-IR score is performed in LipoScience's CLIA certified laboratory.
1. Brunzell John D, Davidson Michael, Furberg Curt D, et al. Lipoprotein Management in Patient with Cardiometabolic Risk. Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care April 2008 (31);4: 811-821.
How to get the test
Ask your doctor to order the LP-IR score* for you. The test is available to all doctors in the United States.
Click here to print a request for the LP-IR score to give to your doctor.
If you have questions about your results, please call your doctor.
* The LP-IR score is performed in LipoScience's CLIA certified laboratory.
Understanding Your Results
The Lipoprotein Insulin Resistance (LP-IR) Score* assesses the patient's insulin resistance level and diabetes risk. This score (0-100) is derived using the results from six lipoprotein markers.
Therapeutic lifestyle changes may reduce the score.1,2
Improved diet and exercise is an important part of your overall heart health and may lower your LDL particle number. LipoScience developed a resource based on the well documented Mediterranean diet and tips to help you get moving to assist in your efforts for a healthy lifestyle. Click here to download the brochure.
* The LP-IR score is performed in LipoScience's CLIA certified laboratory.
1. Genuth and Kahn. Diabetes Care. 2008;31:1096-1096. 2. Insulin Resistance and Pre-Diabetes. 2008. U.S. Department of Health & Human Services. NIH Publication No. 09-4893. Available from www.diabetes.niddk.nih.gov. 3. Reference population comprised 4,588 men and women not on lipid medication enrolled in the Multi-Ethnec Study of Atherosclerosis (MESA).
Reimbursement
The test is reimbursed by Medicare and other health insurance plans.
If you have any questions, a LipoScience Accounts Receivable Specialist is available at (866) 547-0245 Monday through Friday (8:30am through 5:00pm ET).
If you receive an invoice and have questions, please contact your laboratory provider or LipoScience.
* The LP-IR score is performed in LipoScience's CLIA certified laboratory.
Online Bill Payments
We're sorry, the Per Your Health website link is out of service.
If you would like to make a payment by phone, please call our billing department toll-free at (866) 547-0245, Monday through Friday (8:30am - 5:00pm ET).
We accept VISA, MasterCard, American Express, and Discover.